GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Shiller PE Ratio

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Shiller PE Ratio : (As of May. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Scinai Immunotherapeutics Shiller PE Ratio Historical Data

The historical data trend for Scinai Immunotherapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Shiller PE Ratio Chart

Scinai Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scinai Immunotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scinai Immunotherapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Scinai Immunotherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Shiller PE Ratio falls into.



Scinai Immunotherapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Scinai Immunotherapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Scinai Immunotherapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-8/129.4194*129.4194
=-8.000

Current CPI (Dec. 2023) = 129.4194.

Scinai Immunotherapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -17.191 99.695 -22.317
201406 -19.819 100.560 -25.507
201409 -14.947 100.428 -19.262
201412 -11.281 99.070 -14.737
201503 -16.721 99.621 -21.723
201506 -52.914 100.684 -68.016
201509 1.010 100.392 1.302
201512 -31.205 99.792 -40.469
201603 -10.580 100.470 -13.628
201606 -20.747 101.688 -26.405
201609 -21.308 101.861 -27.073
201612 -19.522 101.863 -24.803
201703 -77.277 102.862 -97.229
201706 -80.282 103.349 -100.534
201709 11.332 104.136 14.083
201712 -59.661 104.011 -74.235
201803 -56.954 105.290 -70.007
201806 -109.344 106.317 -133.104
201809 -11.072 106.507 -13.454
201812 -183.948 105.998 -224.594
201903 2.205 107.251 2.661
201906 -201.463 108.070 -241.263
201909 -57.414 108.329 -68.592
201912 -117.090 108.420 -139.769
202003 -11.203 108.902 -13.314
202006 -116.034 108.767 -138.066
202009 115.998 109.815 136.706
202012 -35.639 109.897 -41.970
202103 -23.958 111.754 -27.745
202106 -36.857 114.631 -41.612
202109 -24.844 115.734 -27.782
202112 -17.889 117.630 -19.682
202203 -12.000 121.301 -12.803
202206 -16.000 125.017 -16.563
202209 40.000 125.227 41.339
202212 -36.000 125.222 -37.207
202303 -12.000 127.348 -12.195
202306 -12.000 128.729 -12.064
202309 8.000 129.860 7.973
202312 -8.000 129.419 -8.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Scinai Immunotherapeutics  (NAS:SCNI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Scinai Immunotherapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6